{"filing":{"accession_number":"0001808805-26-000030","cik":"0001808805","ticker":"NAUT","company_name":"Nautilus Biotechnology, Inc.","form":"8-K","filing_date":"2026-07-27","report_date":"2026-07-28","primary_document":"naut-20260728.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000030/naut-20260728.htm"},"events":[{"id":20819,"run_id":18738,"accession_number":"0001808805-26-000030","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release discloses quarterly financial results including revenue of $0.2 million, operating expenses of $15.9 million, and net loss of $14.5 million, along with condensed consolidated financial statements and cash position of $129.2 million. The disclosure is material as it reports the company's first revenue recognition and provides investors with updated financial performance and business developments.","company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","filing_date":"2026-07-27","form":"8-K","submitted_at":null,"items":[{"id":20297,"accession_number":"0001808805-26-000030","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release discloses quarterly financial results including revenue of $0.2 million, operating expenses of $15.9 million, and net loss of $14.5 million, along with condensed consolidated financial statements and cash position of $129.2 million. The disclosure is material as it reports the company's first revenue recognition and provides investors with updated financial performance and business developments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:05:03.310400+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20297,"accession_number":"0001808805-26-000030","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release discloses quarterly financial results including revenue of $0.2 million, operating expenses of $15.9 million, and net loss of $14.5 million, along with condensed consolidated financial statements and cash position of $129.2 million. The disclosure is material as it reports the company's first revenue recognition and provides investors with updated financial performance and business developments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:05:03.310400+00:00","company_name":"Nautilus Biotechnology, Inc.","ticker":"NAUT","filing_date":"2026-07-27"}]}